Dose-Ranging Study to Evaluate Efficacy and Safety of Weekly CJC-1134-PC in Patients With T2DM on Metformin Monotherapy

Summary

DM200-103 is a dose-ranging study to evaluate the efficacy and safety of 17 weeks of weekly injections of CJC-1134-PC in patients with Type 2 Diabetes Mellitus on metformin monotherapy.

Timeline

Start

2011-09

Primary completion

2012-05

Completion

2013-03

Outcome

Outcome not reported

Stopped (Business): “Business decision”

Drugs

Indications